best tesamorelin dosage: Frequently asked questions

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since your usual injection time. If more than 12 hours have passed, skip the missed dose and resume your regular schedule the following day. Do not double-dose. Tesamorelin's GH-stimulating effect is time-dependent: the pituitary response to GHRH peaks 30–90 minutes post-injection and returns to baseline within 4–6 hours, so there's no cumulative therapeutic value in "making up" a missed dose 18–24 hours late.

These are growth hormone-mediated side effects occurring in 15–25% of patients, caused by fluid retention and soft tissue expansion. Symptoms typically resolve within 4–8 weeks as GH receptor downregulation occurs. If persistent or severe, reduce dose to 1mg daily for 2 weeks before re-escalating. This allows tissue adaptation without losing VAT reduction momentum. Do not stop abruptly unless symptoms include visual changes or severe headache, which may indicate pituitary adenoma growth.

No. Patients with lean NASH or predominantly subcutaneous fat distribution show minimal hepatic benefit from tesamorelin regardless of dose. The mechanism requires visceral adiposity reduction to lower portal free fatty acid flux. If your baseline VAT volume is <1600 cm³ (roughly waist circumference <94cm men, <80cm women), consider semaglutide or pioglitazone instead. Both show hepatic benefit independent of VAT.

Injection site erythema, pruritus, or mild swelling affects 30% of patients during initial titration but typically resolves by week 12 as local tissue adapts to repeated administration. If reactions persist or worsen after three months, review injection technique. Injecting too superficially (into dermis rather than subcutaneous fat) or reusing sites too frequently are the most common causes. If technique is correct and reactions continue, discuss dose reduction to 1mg daily with your prescribing physician. Some patients maintain partial VAT response at lower doses with improved local tolerance.

No. Administer your regular 2mg dose at the next scheduled time and continue the protocol without adjustment. Doubling the dose creates a supraphysiological GH spike that increases adverse events (joint pain, edema) without compensating for the missed lipolytic signaling from the previous day. Missing 1-2 doses per month has minimal impact on total VAT reduction, but missing more than 3 consecutive doses resets the cumulative ATGL upregulation timeline by approximately 10 days. If you miss doses frequently due to travel or storage challenges, consider whether the protocol fits your lifestyle. Inconsistent dosing produces inconsistent results.

No. Take the missed dose as soon as you remember if fewer than 12 hours have passed, then resume your regular schedule. If more than 12 hours have elapsed, skip the missed dose entirely and continue with your next scheduled injection. Doubling the dose (4mg) produces no additional GH release because GHRH receptors are already saturated at 2mg. The extra peptide circulates unbound and increases side effect probability (joint pain, fluid retention) without therapeutic benefit. Missing occasional doses delays VAT reduction progress proportionally but does not negate prior weeks' effects.

Discard the reconstituted vial immediately and start fresh with sterile water. Benzyl alcohol in bacteriostatic water binds to hydrophobic peptide regions within hours, disrupting the tertiary structure required for GHRH receptor binding. Even if you catch the error within 24 hours, bioavailability has already dropped 20-30% and will continue declining. There's no salvaging a bacteriostatic-reconstituted vial. The lyophilised powder itself remains viable (assuming it wasn't exposed to moisture), so you're only losing the reconstitution water, not the entire peptide supply.

Arthralgia (joint pain) occurs in 18-22% of tesamorelin patients and typically peaks during weeks 4-8 before resolving spontaneously as the body adapts to elevated GH levels. Reducing the dose to 1.5mg or 1mg does decrease joint pain incidence but also reduces VAT reduction proportionally. Most patients who tolerate the discomfort through week 12 report complete resolution without dose adjustment. If pain persists beyond 12 weeks or limits daily function, consult your prescriber before modifying the dose. Switching injection sites or adjusting timing relative to meals resolves symptoms in 40% of cases without compromising efficacy.

Reassess VAT reduction with imaging. If VAT has declined by >10% but hepatic fat remains stable, continue through 26 weeks, as hepatic lipid clearance lags VAT loss by 2–3 months. If VAT hasn't declined, the issue is likely administration technique (improper reconstitution, inconsistent injection timing) or peptide degradation from temperature excursions during storage. Tesamorelin stored above 8°C loses potency irreversibly.

Verify three factors before concluding non-response: (1) Confirm you're storing reconstituted vials at 2-8°C consistently and using each vial within 14 days. (2) Measure baseline and current IGF-1. If your IGF-1 hasn't increased by at least 30-40 ng/mL from baseline, either the peptide is degraded or your pituitary GHRH receptors are downregulated. (3) Ensure you're measuring visceral adipose tissue correctly through DEXA or CT imaging. Waist circumference and body weight are unreliable proxies because tesamorelin preserves lean mass while reducing VAT, often resulting in stable weight despite significant body composition change. If all three factors check out and IGF-1 rose appropriately but VAT didn't decrease, you may be in the 15-20% of patients with high baseline GH status who respond minimally to GHRH analogs.

VAT rebound during active therapy suggests one of three scenarios: (1) dietary changes that increased caloric surplus beyond tesamorelin's lipolytic capacity, (2) development of antiretroviral therapy (ART) regimen changes that worsen lipodystrophy independent of tesamorelin, or (3) antibody-mediated neutralisation of tesamorelin (rare, documented in fewer than 2% of patients). Repeat imaging to confirm VAT increase, then work with your provider to assess dietary patterns and ART regimen stability before considering tesamorelin discontinuation.

Increase to 1.5mg for an additional eight weeks before concluding non-response. Cognitive effects from BDNF upregulation and hippocampal neurogenesis operate on a 6-12 week timeline. Structural brain changes precede subjective improvements in memory and executive function. Verify reconstitution technique (no shaking, refrigerated storage) and injection timing (30-60 minutes pre-sleep). If IGF-1 levels remain below 180 ng/mL after eight weeks at 1.5mg, you may be a low responder requiring 2mg, though doses above this threshold offer no additional cognitive benefit and increase metabolic side effects.

Discard the vial immediately. Cloudiness indicates peptide aggregation and loss of bioactivity. Do not inject cloudy solutions under any circumstance. The most common cause is a brief temperature excursion (refrigerator malfunction, leaving the vial out during dose preparation). Peptides like Cerebrolysin and tesamorelin are irreversibly damaged by heat exposure. Refrigeration after the fact does not restore potency. Reconstitute a fresh vial and verify your refrigerator maintains 2-8°C consistently using a dedicated thermometer.

Reduce to 1mg immediately and reassess after two weeks. Joint symptoms resolve in 80% of cases within 10-14 days of dose reduction. The mechanism is GH-induced fluid retention in joint spaces and carpal tunnel compression, which occurs more frequently at doses above 1.5mg and does not contribute to cognitive enhancement. Continuing at 2mg despite symptoms risks chronic carpal tunnel syndrome requiring surgical intervention. The cognitive plateau occurs at 1.5mg, so dose reduction does not sacrifice brain health benefits.

No. Doses above 2mg increase glucose intolerance and side effects without reliably improving fat loss. Non-response at week 12 indicates metabolic resistance, not insufficient dosing. Check thyroid function (TSH, free T4) and insulin sensitivity (fasting insulin, HOMA-IR). Untreated hypothyroidism or severe insulin resistance block tesamorelin's lipolytic signaling. Address those conditions first; raising the peptide dose compounds the glucose problem without solving the underlying metabolic block.

Not immediately, but intervention is required. First, confirm the elevation with a repeat fasting glucose test within 3–5 days. If confirmed, add metformin 500mg daily with dinner to improve insulin sensitivity, or reduce tesamorelin to 1.4mg daily. Recheck fasting glucose in 2 weeks. If glucose exceeds 126 mg/dL on two separate tests or HbA1c rises above 6.5%, discontinue tesamorelin and consult your prescribing physician. The metabolic cost outweighs the VAT reduction benefit at that threshold.

No. Never double-dose to compensate for a missed injection. Resume your normal 2mg dose the following evening and continue the regular schedule. Tesamorelin's mechanism relies on consistent pulsatile GH stimulation; doubling the dose creates a supraphysiologic GH spike that increases hyperglycemia risk and fluid retention without improving VAT reduction. Missing 1–2 doses per month has minimal impact on overall efficacy as long as the pattern isn't chronic.

Reduce your dose to 1.5mg daily for two weeks, then attempt to re-escalate to 2mg if symptoms resolve. Arthralgias occur in 5–8% of patients at 2mg daily and are caused by transient fluid retention in joint spaces as IGF-1 levels rise. The effect is self-limiting in most cases. Symptoms peak during weeks 2–4 and resolve by week 6–8 as the body adjusts to elevated IGF-1. If pain persists beyond eight weeks or worsens over time, discontinue tesamorelin and consult your supervising physician. Persistent arthralgias may indicate underlying inflammatory arthritis unmasked by GH stimulation rather than a direct peptide side effect.

Administer the missed dose as soon as you remember if fewer than 12 hours have passed since your scheduled injection time, then resume your regular schedule the next day. If more than 12 hours have passed, skip the missed dose entirely and continue with your next scheduled injection. Do not double-dose to compensate. Doubling doses does not produce twice the GH pulse; it saturates GHRH receptors without additional benefit while increasing the risk of arthralgias and injection site reactions. Missing occasional doses during the first month of treatment may slow initial VAT reduction but does not eliminate cumulative benefit if consistency is restored.

Discard the vial if it remained at room temperature (above 8°C) for more than 8 hours. Peptide stability at ambient temperature is limited to 72 hours maximum under controlled conditions, but that assumes consistent room temperature (20–22°C). Not fluctuating household conditions where temperatures may exceed 25°C. Visual inspection is unreliable: degraded tesamorelin remains a clear, colourless solution indistinguishable from active peptide. Injecting degraded peptide will not cause acute harm, but it delivers zero therapeutic effect. Essentially an expensive saline injection. Replace the vial rather than risk wasting weeks of a protocol on inactive compound.